Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
3.87
Dollar change
+0.04
Percentage change
1.04
%
IndexRUT P/E- EPS (ttm)-0.62 Insider Own19.54% Shs Outstand120.22M Perf Week-0.77%
Market Cap468.32M Forward P/E- EPS next Y-0.36 Insider Trans0.00% Shs Float97.37M Perf Month-14.00%
Income-63.02M PEG- EPS next Q-0.10 Inst Own54.31% Short Float7.57% Perf Quarter-2.52%
Sales20.41M P/S22.95 EPS this Y-7.60% Inst Trans2.60% Short Ratio17.72 Perf Half Y-16.23%
Book/sh2.43 P/B1.59 EPS next Y33.88% ROA-17.43% Short Interest7.37M Perf Year-19.38%
Cash/sh0.49 P/C7.89 EPS next 5Y- ROE-20.45% 52W Range3.56 - 6.72 Perf YTD-37.28%
Dividend Est.- P/FCF- EPS past 5Y- ROI-20.21% 52W High-42.37% Beta-0.11
Dividend TTM- Quick Ratio4.62 Sales past 5Y13.92% Gross Margin-2.46% 52W Low8.71% ATR (14)0.20
Dividend Ex-Date- Current Ratio4.62 EPS Y/Y TTM-111.80% Oper. Margin-402.81% RSI (14)45.07 Volatility3.34% 5.26%
Employees106 Debt/Eq0.08 Sales Y/Y TTM-68.45% Profit Margin-308.78% Recom1.00 Target Price9.75
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q-1.52% Payout- Rel Volume0.88 Prev Close3.83
Sales Surprise-50.39% EPS Surprise-16.36% Sales Q/Q-23.83% EarningsNov 12 AMC Avg Volume415.97K Price3.87
SMA20-4.11% SMA50-4.46% SMA200-13.70% Trades Volume369,118 Change1.04%
Date Action Analyst Rating Change Price Target Change
Nov-29-23Initiated RBC Capital Mkts Outperform $6
Apr-21-23Initiated The Benchmark Company Buy $8
Apr-13-23Initiated Craig Hallum Buy $10
Feb-22-23Initiated Cowen Outperform $10
Feb-13-23Initiated H.C. Wainwright Buy $11
Dec-20-22Initiated Truist Buy $10
Dec-16-22Initiated Credit Suisse Outperform $13
Nov-29-22Initiated SVB Leerink Outperform $6
Nov-28-22Initiated Stifel Buy $12
Nov-12-24 04:05PM
Oct-30-24 08:00AM
Oct-22-24 08:00AM
Aug-26-24 08:00AM
Aug-08-24 04:05PM
08:00AM Loading…
Jul-25-24 08:00AM
Jun-03-24 04:05PM
May-20-24 08:05AM
May-15-24 04:05PM
May-12-24 03:24PM
May-09-24 08:56PM
04:05PM
May-01-24 08:00AM
Apr-22-24 08:00AM
Mar-21-24 11:31AM
08:54PM Loading…
Mar-20-24 08:54PM
04:05PM
Feb-28-24 08:27AM
Feb-26-24 08:00AM
Feb-20-24 08:00AM
Dec-14-23 04:30PM
Nov-20-23 12:39PM
Nov-14-23 05:03AM
Nov-09-23 05:55PM
09:24AM
08:00AM
Nov-02-23 08:00AM
Nov-01-23 09:00AM
Oct-31-23 04:28PM
Oct-26-23 02:32PM
08:00AM Loading…
Oct-12-23 08:00AM
Sep-05-23 08:00AM
Aug-15-23 05:20AM
Aug-13-23 08:06AM
Aug-10-23 04:05PM
Aug-07-23 04:05PM
Jul-31-23 08:00AM
Jul-17-23 07:35AM
Jun-13-23 06:00AM
May-18-23 05:09PM
May-17-23 04:05PM
May-16-23 06:06AM
May-14-23 08:03AM
May-11-23 10:55PM
07:00AM
May-05-23 07:14AM
May-04-23 06:26AM
May-01-23 08:00AM
Apr-26-23 08:01PM
Apr-25-23 08:00AM
Apr-19-23 08:30AM
Apr-07-23 10:24PM
Apr-05-23 06:09AM
Apr-02-23 08:51AM
Mar-31-23 08:40AM
Mar-30-23 04:05PM
Mar-15-23 11:44AM
Mar-09-23 08:00AM
Mar-08-23 09:53AM
Feb-23-23 07:49AM
Feb-07-23 08:00AM
Feb-01-23 06:56AM
Dec-16-22 12:39PM
Dec-01-22 08:47AM
Nov-15-22 07:00AM
Nov-03-22 08:00AM
Nov-02-22 07:00AM
Nov-01-22 04:01PM
04:01PM
OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOEHR MATTHEW WPresident and CEONov 25 '24Option Exercise3.7399,434370,7023,698,600Nov 26 04:41 PM
Avista Capital Managing Member10% OwnerJun 29 '24Option Exercise3.3566,668223,33815,992,372Jul 02 05:00 PM
FOEHR MATTHEW WPresident and CEOJun 27 '24Option Exercise3.7359,659222,4163,599,166Jun 27 04:55 PM
FOEHR MATTHEW WPresident and CEOMay 24 '24Buy4.42240,0001,059,8403,536,665May 28 05:55 PM
GUSTAFSON KURT AExecutive VP, Finance and CFOApr 08 '24Sale5.276,95436,648176,697Apr 09 06:38 PM
Berkman Charles SChief Legal OfficerApr 08 '24Sale5.276,95436,648292,617Apr 09 06:37 PM
GUSTAFSON KURT AExecutive VP, Finance & CFOApr 01 '24Sale5.4611,84964,696170,110Apr 02 06:30 PM
FOEHR MATTHEW WPresident and CEOMar 27 '24Option Exercise3.72243,613907,0233,152,416Mar 29 04:52 PM
FOEHR MATTHEW WPresident and CEOMar 22 '24Buy5.19225,0001,167,7502,908,803Mar 25 07:07 AM
FOEHR MATTHEW WChief Executive OfficerDec 12 '23Buy5.05200,0001,010,0002,645,442Dec 13 03:25 PM